Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial

Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial

Abstract Background Hepatocellular carcinoma (HCC) accounts for 75–85% of primary liver cancers and is prevalent in the Asia-Pacific region. Till now, trans-arterial chemoembolization (TACE) is still one of common modalities in managing unresectable intermediate-stage HCC. However, post-TACE residua...

Full description

Bibliographic Details
Main Authors: Liang-Cheng Chen, Wen-Yen Chiou, Hon-Yi Lin, Moon-Sing Lee, Yuan-Chen Lo, Li-Wen Huang, Chun-Ming Chang, Tsung-Hsing Hung, Chih-Wen Lin, Kuo-Chih Tseng, Dai-Wei Liu, Feng-Chun Hsu, Shih-Kai Hung
Format: Article
Language:English
Published: BMC 2019-03-01
Series:BMC Cancer
Subjects:
Hepatocellular carcinoma (HCC)
Trans-arterial chemoembolization (TACE)
Stereotactic ablative radiotherapy (SABR)
Stereotactic body radiation therapy (SBRT)
Online Access:http://link.springer.com/article/10.1186/s12885-019-5461-3

Internet

http://link.springer.com/article/10.1186/s12885-019-5461-3

Similar Items